A retrospective study in Chinese patients found no significant benefit in RFS or distant metastasis-free survival (DMFS) with adjuvant anti-PD-1 treatment compared to adjuvant HD-IFN in AM patients, although such benefits were observed in CM patients [108]. Here, IFNA1 is linked to acute myeloblastic leukemia with maturation.